DC
ADMA icon

Diametric Capital’s ADMA Biologics ADMA Stock Holding History

Diametric Capital’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-52,005
Closed -$469K – 477
2026
Q1 		$469K Buy
+52,005
New +$821K 0.12% 233
2020
Q4 		– Sell
-48,355
Closed -$116K – 162
2020
Q3 		$116K Buy
+48,355
New +$133K 0.09% 111

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Diametric Capital's ADMA Position: Q2 2026 in Review

Diametric Capital sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 52,005 shares — an estimated $469K sold.

Diametric Capital first reported a position in ADMA in Q3 2020 and held it in 2 quarters. The position peaked at $469K in Q1 2026. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Diametric Capital reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Diametric Capital sold 52,005 ADMA Biologics shares in Q2 2026, an estimated $469K.
  • Diametric Capital first reported a position in ADMA Biologics in Q3 2020 and held it in 2 quarters.
  • Diametric Capital's ADMA Biologics position peaked at $469K in Q1 2026.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.